Investors & Media

Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment

Phase 2b RE-THINC ESRD study of fesomersen met its primary endpoint in patients with end-stage renal disease on hemodialysis Fesomersen demonstrated substantial and statistically significant reductions in Factor XI activity levels Fesomersen, a novel Factor XI antisense inhibitor designed to

Read more
You are now leaving to visit